Novartis AG - End Period Cash Flow

Novartis AG's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "End-Period-Cash-Flow" stands at 34.74 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 06/30/2023.

Novartis AG's third quarter result of 9.56 Billion USD for the item "End Period Cash Flow" represents an increase of 43.57 percent compared to it's second quarter result.

Also, Novartis AG's third quarter result of 9.56 Billion USD for the item "End Period Cash Flow" represents a decrease of -29.78 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Novartis AG's third quarter result of 34.74 Billion USD for the item "End Period Cash Flow" represents a decrease of -10.45 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes a decrease of -21.33 percent compared to the value the year prior.
The 1 year change in percent is -21.33.
The 3 year change in percent is -10.03.
The 5 year change in percent is 13.70.
The 10 year change in percent is 15.63.

The Serie's long term average value is 31.53 Billion United States Dollars. It's latest available value, on 09/30/2025, is 10.16 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 03/31/2012, to it's latest available value, on 09/30/2025, is +116.20%.
The Serie's change in percent from it's maximum value, on 12/31/2023, to it's latest available value, on 09/30/2025, is -28.28%.